Clinical trial
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic…
NCT00086957 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00086957 |
|---|---|
| Title | Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, docetaxel, gefitinib |
| Enrollment | 31 |
| Start date | Jan 1, 2004 |
| Primary completion | Aug 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Jul 12, 2004 |
| Last update posted | Feb 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: